Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

New Cancer Diagnoses Still Lagging in the United States in Second Full Year of COVID-19 Pandemic

New Cancer Diagnoses Still Lagging in the United States in Second Full Year of COVID-19 Pandemic

Authors: Kaufman HW, Chen Z, Niles J, Fesko Y

Citation: JCO Clin Cancer Inform. 2022;(6):e2200102. doi: 10.1200/CCI.22.00102.

Specialty: Oncology, Infectious disease, COVID-19

 

Download key summary

Related content

Audio Podcast
Optimize Oncology Care with Clinical Pathways
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
On-Demand Webinar
Hereditary Cancer Care Starts in Primary Care
On-Demand Webinar
Early Detection Better Protection - Colorectal Cancer Screening in the Workplace: A Panel Discussion
On-Demand Webinar
Precision Medicine: Your Role in Advancing the Future of Cancer Care

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.